0.36
+1.41%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Modern Chinese Medicine Group Co
Its shares trade on HKEX under the ticker 1643.HK. It has been listed since 15 January 2021. In the fiscal year to 31 December 2025, it reported revenue of CN¥141.4m and a net loss of CN¥13.2m. At that date it held total assets of CN¥543.6m and shareholders' equity of CN¥498.2m.
Modern Chinese Medicine Group Co., Ltd. is an investment holding company, which engages in the distribution of medicines under the Yushi brand. The company is headquartered in Chengde, Hebei. The company went IPO on 2021-01-15. The firm mainly provides over-the-counter (OTC) and prescribed medicine intended for use by the middle-aged and elderly people. The firm's main products are Vigour and Vitality Supplement Pill, Circulation Enhancement Pill, Cardiotonic Enhancement Capsule, Kidney Invigoration Pill, Heart Wellness Capsule, Menstrual Discomfort Relief Pill, Liver Detox Tablet, Additional Ingredient Huoxiang ZhengQi Pill and Fever-removing and Detoxremoving Pill. The firm is also engaged in the production of other traditional Chinese medicines designed to treat or relieve other conditions such as psychological, respiratory, and pediatric conditions. The firm mainly conducts business within the domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 15 Jan 2021
- Employees
- 192
- Website
- cdysjdyy.com ↗
Leadership
Pay as last reported
- Ms. Xinlei SunExecutive Chairman of the Board, since 2023
- Ms. Hongli ZhangChief Executive Officer, Executive Director, since 2019CN¥271,000
- Mr. Wen Tao LiChief Financial Officer
- Ms. Yanru JiaExecutive Director, Joint Company Secretary, since 2021
- Ms. Yuen Ting TseJoint Company Secretary
- Mr. Tsz Wing LeungNon-Executive Independent DirectorCN¥103,000
- Ms. Ling LiuNon-Executive Independent DirectorCN¥103,000
- Mr. Chi Kin WongNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 73
- Environment
- 78
- Social
- 75
- Governance
- 66
- Direct emissions (scope 1)
- 692 t
- Energy emissions (scope 2)
- 9,302 t
- Value chain emissions (scope 3)
- 15,407 t
- Women in the workforce
- 61%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Modern Chinese Medicine Group distributes OTC and prescribed medicines for middle-aged and elderly people.
- The company's main products include Vigour and Vitality Supplement Pill and Circulation Enhancement Pill.
- Chengde, Hebei serves as the headquarters for the investment holding company.
Weaknesses
- The company employs only 192 full-time employees in the domestic market.
- The firm's business is limited to the domestic market in China.
- Modern Chinese Medicine Group went public on 15 January 2021.
Opportunities
- The firm produces traditional Chinese medicines for psychological, respiratory, and pediatric conditions.
- The company's product line includes Heart Wellness Capsule and Liver Detox Tablet.
- The firm's main market is the domestic Chinese market.
Threats
- The company's business is restricted to the domestic market in China.
- The firm has no international presence or expansion plans.
- Modern Chinese Medicine Group is a small company with 192 employees.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.